Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $608.5 million.

  • Spyre Therapeutics' Liabilities and Shareholders Equity rose 19.83% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 31.73%. This contributed to the annual value of $608.5 million for FY2024, which is 77.99% up from last year.
  • Per Spyre Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $608.5 million for FY2024, which was up 77.99% from $341.9 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Liabilities and Shareholders Equity registered a high of $608.5 million during FY2024, and its lowest value of $71.1 million during FY2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $341.9 million (2023), whereas its average is $340.5 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first slumped by 35.28% in 2022, then surged by 380.52% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Liabilities and Shareholders Equity stood at $161.6 million in 2020, then crashed by 31.98% to $109.9 million in 2021, then tumbled by 35.28% to $71.1 million in 2022, then soared by 380.52% to $341.9 million in 2023, then skyrocketed by 77.99% to $608.5 million in 2024.